A new prospective study suggests that an advanced form of magnetic resonance imaging, known as ultrafast dynamic contrast-enhanced MRI, can help clinicians determine whether breast cancer has spread to the axillary lymph nodes before surgery, potentially reshaping how patients are staged and treated. The research, published in BMC Medical Imaging by a team led by Ping Yan and Hong Zhou of the First Affiliated Hospital of Hengyang Medical School, University of South China, reports that two kinetic parameters derived from the earliest seconds of contrast enhancement—time-to-enhancement and maximum slope—were independently predictive of axillary lymph node metastasis in patients with invasive breast cancer.

The axillary lymph nodes, located in the armpit, are typically the first destination for breast cancer cells leaving the primary tumor. Whether or not these nodes contain metastatic disease is one of the most powerful prognostic indicators in breast cancer and directly influences surgical planning, including whether a patient undergoes sentinel lymph node biopsy or a more extensive axillary dissection. Current assessment relies on a combination of physical examination, ultrasound, and pathological evaluation of surgically removed nodes, each of which carries limitations. Imaging-based assessment has long struggled to distinguish metastatic from reactive nodes, since enlarged nodes can be benign and normal-sized nodes can harbor microscopic disease.

Ultrafast dynamic contrast-enhanced MRI addresses this problem by dramatically increasing the temporal resolution of the imaging sequence. In conventional breast MRI, the scanner acquires images over several minutes after injection of a gadolinium-based contrast agent, capturing how tumors take up and wash out contrast. Ultrafast protocols compress the earliest phase of this process into a rapid series of acquisitions lasting only seconds each, allowing radiologists to watch the very first moments of contrast arrival. Because malignant tumors grow new, leaky, and disorganized blood vessels—a process called angiogenesis—their enhancement kinetics differ measurably from those of healthy tissue. The ultrafast approach captures tumor neovascularization, microcirculatory changes, and increased vascular permeability at a stage that conventional sequences simply cannot resolve.

The study enrolled 173 consecutive female participants suspected of having a breast mass, recruited between September 2022 and February 2023, with clinical and immunohistochemical information collected for all subjects. MRI data were collected prospectively and analyzed retrospectively. Ultimately, 114 patients formed the analysis groups: 64 with axillary lymph node metastasis and 50 without. The researchers compared morphological features of the lymph nodes, such as their short and long diameters and the presence of a fatty hilum, with dynamic parameters derived from the ultrafast sequence, including maximum slope and time-to-enhancement.

The results were striking. Among tumor types, invasive carcinoma was significantly associated with axillary lymph node metastasis. For the lymph node measurements themselves, short diameter, long diameter, hilum status, maximum slope, and time-to-enhancement all differed significantly between the metastatic and non-metastatic groups, with p values below 0.001. This means that nodes destined to be positive for metastasis were not only larger and more likely to have lost their normal fatty hilum—the traditional ultrasound and MRI signs of involvement—but also enhanced differently on the ultrafast sequence, lighting up faster and more intensely than their benign counterparts.

Multivariate analysis, which statistically separates the contribution of each factor while accounting for the others, identified three independent predictors of nodal metastasis. Short diameter carried an odds ratio of 5.705, meaning that each increase in this measure multiplied the odds of metastasis more than fivefold. Maximum slope was the strongest predictor, with an odds ratio of 9.584, while time-to-enhancement was protective in direction, with an odds ratio of 0.201, reflecting that nodes that enhanced more slowly were less likely to be metastatic. These findings make physiological sense: a metastatic node replaced by tumor tissue develops the same chaotic, hyperpermeable vasculature as the primary cancer, producing rapid, steep contrast uptake that the ultrafast sequence records in real time.

Perhaps most importantly, the researchers found that combining the parameters outperformed any single measure. The combined model achieved an area under the receiver operating characteristic curve of 0.916, significantly better than time-to-enhancement, maximum slope, or short diameter alone. An AUC of 0.916 indicates excellent discriminatory power—well above the 0.8 threshold generally considered good and approaching the 0.9 range regarded as excellent. The team used the Youden index to determine optimal diagnostic thresholds and applied the DeLong test to confirm that the combined model’s advantage over individual parameters was statistically significant rather than a chance finding.

The clinical implications could be substantial. Sentinel lymph node biopsy, while far less invasive than full axillary dissection, still carries risks of lymphedema, nerve injury, and seroma formation, and requires surgery to obtain its answer. A reliable preoperative imaging biomarker of nodal status could help stratify patients, identify those who might safely avoid more extensive procedures, and inform neoadjuvant treatment decisions before the operating room. The authors note that the ultrafast kinetic parameters showed great clinical value not only for diagnosis but also for screening, treatment planning, and prognosis evaluation in breast cancer. Because the sequence adds only seconds to a standard breast MRI protocol, it could be integrated into existing workflows without meaningful increases in scan time or cost.

The study also has limitations worth noting. The analysis involved 114 evaluable patients from a single institution in Hunan, China, and the authors describe the work as a retrospective analysis of prospectively collected data. The study was approved by the Ethics Committee of the First Affiliated Hospital of University of South China and registered under ChiCTR2200065443, with informed consent requirements waived for anonymized clinical data. Validation in larger, multicenter cohorts will be needed before the combined model can be adopted as a standard of care, and the technology requires MRI scanners and software capable of ultrafast acquisition, which are not universally available. The research was supported by the Science and Technology Program of Hunan Province and related provincial and hospital funding programs, and the authors declare no competing interests, although two co-authors are affiliated with Siemens Healthineers, the manufacturer whose MR platforms commonly support ultrafast sequences.

Nevertheless, the study adds to a growing body of evidence that the richest diagnostic information in MRI lies not in static pictures but in the physics of how contrast moves through living tissue. By capturing the first seconds of that movement, ultrafast dynamic contrast-enhanced MRI turns a routine staging question—has the cancer reached the lymph nodes?—into a measurable kinetic signature. If future validation confirms these results, the seconds immediately after contrast injection could become one of the most informative moments in breast cancer imaging, offering patients a noninvasive answer to a question that today still requires a scalpel.

Subject of Research: Ultrafast dynamic contrast-enhanced MRI for detecting axillary lymph node metastases in invasive breast cancer

Article Title: Prospective evaluation of Ultrafast Dynamic Contrast-Enhanced MRI for axillary lymph node metastases in invasive breast cancer

Article References: Yan, P., Zeng, Y., Song, W., Zhang, H., Grimm, R., He, L., Liu, W., & Zhou, H. (2026). Prospective evaluation of Ultrafast Dynamic Contrast-Enhanced MRI for axillary lymph node metastases in invasive breast cancer. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02712-6

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02712-6

Keywords: breast cancer, ultrafast DCE-MRI, axillary lymph node metastasis, MRI kinetics, time-to-enhancement, maximum slope, cancer imaging, radiology, sentinel lymph node, tumor angiogenesis, ROC analysis, diagnostic imaging